Urinary estrogen metabolites and prostate cancer: A case-control study in the United States

Cancer Causes and Control

Volumn 13, Issue 10, 2002, Pages 947-955

  Muti, Paola ^a   Westerlind, Kim ^b   Wu, Tiejian ^a   Grimaldi, Thomas ^c   De Berry, John ^d   Schünemann, Holger ^a,e   Freudenheim, Jo L ^a   Hill, Helyn ^a   Carruba, Giuseppe ^f   Bradlow, Leon ^g  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f UNIVERSITY OF PALERMO   (Italy)

^g Inst for Biochemical Research HUMC   (United States)

Author keywords

Estrogen metabolites; Prostate cancer risk

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CLINICAL PATHWAY; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMANS; HYDROXYESTRONES; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW YORK; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 12244272389     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021986811425     Document Type: Article

References (41)

1. Hsing AW, Tsao L, Devesa SS (2000) International trends in prostate cancer incidence and mortality. Int J Cancer 85: 60-67.
2. Nomura AMY, Kolonel LN (1991) Prostate cancer: a current prospective Am J Epidemiol 13: 200-227.
3. Castagnetta L, Miceli MD, Sorci C, et al. (1995) Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136: 2309-2319.
4. Carruba G, Miceli MD, Comito L, et al. (1996) Multiple estrogen function in human prostate cancer cells. Ann NY Acad Sci 784: 70-84.
5. Clark JK, Paszko Z, Peck EJ (1977) Nuclear binding and retention of the receptor estrogen complex: relation to the agonist and antagonist properties of estriol. Endocrinology 100: 91-96.
6. Westerlind KC, Gibson KJ, Malone P, Evans GL, Turner RT (1998) Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. J Bone Mineral Res 13: 1023-1031.
7. Lotinun P, Westerlind KC, Turner RT (2001) Tissue-selective effects of continuous release of 2-hydroxyestrone and 16α-hydroxyestrone on bone, uterus, and mammary gland in ovariectomized growing rats. J Endocrinol 170: 165-174.
8. Telang NT, Suto A, Wong GY, Osborn MP, Bradlow HL (1992) Induction by estrogen metabolite 16α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84: 634-638.
9. Martucci C, Fishman J (1977) Direction of estradiol metabolism as a control of its hormonal action - uterotrophic activity of estradiol metabolism. Endocrinology 101: 1709-1715.
10. Suto A, Bradlow HL, Wong GY, Osborne MP, Telang NT (1993) Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat 27: 193-202.
11. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J (1985) Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA 82: 6295-6299.
12. Osborne MP, Bradlow HL, Wong GYC, Telang NT (1993) Upregulation of estradiol C16α-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 85: 1917-1920.
13. Ursin G, Londo S, Stanczky FZ, et al. (1997) A pilot study of urinary estrogen metabolism (16α-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. Environ Health Perspect 105 (Suppl. 3): 601-605.
14. Kabat GC, Chang CJ, Sparano JA, et al. (1997) Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 6: 505-509.
15. Zheng W, Dunning L, Jin F, Holtzman J (1997) Correspondence re: Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 6: 500-504.
16. Meilahn EN, De Stavola B, Allen DS, et al. (1998) Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 78: 1250-1255.
17. Muti P, Micheli A, Krogh V, et al. (2000) Estrogen metabolism and breast cancer risk. Epidemiology 11: 635-640.
18. Catalona WJ (1987) Diagnosis, staging, and surgical treatment of prostatic carcinoma. Arch Intern Med 147: 361-380.
19. Breslow N, Chan CW, Dhorn G (1977) Latent carcinoma of prostate at authopsy in seven areas. Int J Cancer 20: 680-688.
20. Bostwick DG, Cooner WH, Denis L (1992) The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70: 291-301.
21. Babaian RJ, Mettlin C, Kane R (1992) The relationship of prostate-specific antigen to digital examination and transrectal ultrasonography. Findings of the America Cancer Society National Prostate Cancer Detection Project. Cancer 69: 1195-1200.
22. Bradlow HL, Sepkovic DW, Klug T, Osborne MP (1998) Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 63: 406-413.
23. Klug TL, Bradlow HL, Sepkovic DW (1994) Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16α-hydroxyesterone in urine. Steroids 59: 648-655.
24. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I, Osborne MP (1994) Catechol estrogen production in rat microsomes after treatment with indole-3-carbinol, ascorbigen, or B-napthaflavone: a comparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods. Steroids 59: 318-323.
25. Andersson SO, Adami HO, Bergstrom R, Wide L (1993) Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer - a population based case-control study. Br J Cancer 68: 97-102.
26. Signorello LB, Tzonou A, Mantzoros CS, et al. (1997) Serum steroids in relation to prostate cancer risk in a case-control study (Greece). Cancer Causes Control 8: 632-636.
27. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118-1126.
28. Hsing AW (2001) Hormones and prostate cancer: what's next Epidemiol Rev 23: 42-58.
29. Fishman J (1996) The catechol estrogens. Nearoendocrinology 22: 363-374.
30. Longcope C, Pratt JH (1977) Blood production rate of estrogens in women with differing ratios of urinary estrogen conjugates. Steroids 29: 483-488.
31. Fishman J, Martucci C (1980) Biological properties of 16 alpha-hydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab 51: 611-615.
32. Swaneck GE, Fishman J (1988) Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Nat Acad Sci USA 85: 7831-7835.
33. Yu SC, Fishman J (1985) Interaction of histones with estrogens. Covalent adduct formation with 16 alpha-hydroxyestrone. Biochemistry 24: 8017-8021.
34. Bradlow HL, Hershcopf RJ, Fishman J (1986) Oestradiol 16α hydroxylase: a risk marker for breast cancer. Cancer Surv 5: 573-583.
35. Fishman J, Schneider J, Hershcoff RJ, Bradlow HL (1984) Increased estrogen 16α hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 20: 1077-1081.
36. Castagnetta L, D'Agostino G, Lo Casto M, Traina A, Leake RE (1981) Breast cancer: a comparison of response to endocrine therapy and oestrogen excretion patterns including unusual metabolites. Br J Cancer 44: 670-674.
37. Castagnetta L, D'Agostino G, Granata OM, Traina A, Leake RE (1983) Studies on oestrogen status and oestrogen hormone sensitivity in advanced endometrial cancer. In: Flamigni C, Jasonni V, Nenci I, eds. Steroids and Endometrial Cancer. New York: Raven Press, pp. 233-236.
38. Stone NN, Fair WR, Fishman J (1986) Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. Prostate 9: 311-318.
39. van Landeghem AAJ, Poortman J, Nabuurs M, Thijssen JHH (1985) Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45: 2900-2906.
40. Castagnetta L, Granata OM, Arcuri F, et al. (1992) Recent studies on metabolism and concentrations of estrogens in breast cancer tissues and cells. Cancer Detect Prev 16: 65-70.
41. Carruba G, Adamski J, Calabrò M, et al. (1997) Molecular expression of 17β hydroxysteroid dehydrogenase types in relation to their activity in human prostate cancer cells. Mol Cell Endocrinol 135: 51-57.